Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Status: Recruiting
Location: See all (13) locations...
Study Type: Observational
SUMMARY
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:
• Patients 40 years of age and older
• diagnosed with Smoldering Multiple Myeloma
• dFLC greater than 23 mg/L
• abnormal FLC ratio
• If the patient has an eGFR less than 50 mL/min/1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion.
Locations
United States
Alabama
University of Alabama Hospital
RECRUITING
Birmingham
California
Cedars-Sinai Medical Center
NOT_YET_RECRUITING
Los Angeles
University of California, Irvine
NOT_YET_RECRUITING
Orange
University of California, San Francisco
NOT_YET_RECRUITING
San Francisco
Florida
Cleveland Clinic Florida, Weston Hospital
NOT_YET_RECRUITING
Weston
Massachusetts
Tufts Medical Center
RECRUITING
Boston
North Carolina
Atrium Health Levine Cancer Institute
RECRUITING
Charlotte
UNC Lineberger Comprehensive Cancer Center
RECRUITING
Durham
New York
Columbia University Irving Medical Center
RECRUITING
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Texas
UT Southwestern, Harold C. Simmons Comprehensive Cancer Center
NOT_YET_RECRUITING
Dallas
Utah
University of Utah, Huntsman Cancer Hospital
RECRUITING
Salt Lake City
Virginia
VCU Medical Center
RECRUITING
Richmond
Contact Information
Primary
Raymond Comenzo, MD
raymond.comenzo@tuftsmedicine.org
617-636-6454
Backup
Denis Toskic, BS
denis.toskic@tuftsmedicine.org
617-636-5907
Time Frame
Start Date: 2024-05-01
Estimated Completion Date: 2029-02-27
Participants
Target number of participants: 400
Related Therapeutic Areas
Sponsors
Collaborators: National Cancer Institute (NCI)
Leads: Tufts Medical Center